Humana Inc 8-K, filed Feb 7, 2020
Humana Inc (HUM)
8-K
2020-02-07
For: 2020-02-07
View Original
Added on
April 10, 2026
About this 8-K
Humana Inc filed this 8-K on February 7, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
|
|
FORM
|
|
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of
earliest event reported):
|
|
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
(Address of Principal Executive Offices, and Zip Code)
(502 ) 580-1000
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if
Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Securities registered pursuant to Section
12(b) of the Act:
|
||||
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
||
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to
use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On February 5, 2020, after the stock market closed, the Centers for Medicare and Medicaid
Services (“CMS”) issued Part II of the 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies (the “Advance Notice”). CMS has invited public comment on the Advance Notice before
publishing final rates on April 6, 2020 (the “Final Notice”).
In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on
average, experience a 0.93 percent increase in benchmark funding based on proposals included therein. As indicated by CMS, its estimate excludes the impact of fee for service county rebasing/repricing because the related impact is dependent upon
finalization of certain data, which will be available with the publication of the Final Notice.
Based on Humana Inc.’s (the “Company”) preliminary analysis using the same factors CMS
included in its estimate, the components of which are detailed on CMS’ website, the Company anticipates that the proposals in the Advance Notice would result in a change to its benchmark funding relatively in line with CMS’ estimate. The Company
will be drawing upon its program expertise to provide CMS formal commentary on the impact of the Advance Notice and the related impact upon Medicare beneficiaries’ quality of care and service to its members through the Medicare Advantage program.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HUMANA INC.
|
|
|
BY:
|
/s/ Cynthia H. Zipperle
|
|
|
Cynthia H. Zipperle
|
|
Senior Vice President, Chief Accounting Officer and Controller
(Principal Accounting Officer)
|
|
Dated: February 7, 2020